基因技术公司的抗血管内皮生长因子单克隆抗体 (anti- VEGF)和法玛西亚药厂的血管生成信号抑制剂 SU541 6,均设计为阻断血管内皮生长因子受体 ,阻止肿瘤细胞需要的新血管形成 ,均已显示有令人鼓舞的治疗转移结直肠癌活性。美国每年新诊断为结直肠癌患者有 1 30 0 0 0例 ,其中 5 Gene Technology’s anti-VEGF monoclonal antibody (anti-VEGF) and the phamaceuticals angiogenic signal inhibitor SU541 6 are designed to block the VEGFRs and prevent the need for new tumor cells Angiogenesis has been shown to have encouraging treatment for metastatic colorectal cancer activity. There are 130,000 newly diagnosed colorectal cancer patients each year in the United States, of which 5